Johannes Fruehauf

ViThera Laboratories develops novel biotherapeutics on the basis of engineered probiotic bacteria. ViThera also offers contract biology laboratory services in the heart of Kendall Square, Cambridge, MA.

At Aura, I coordinate all internal and external research and development activities for Aura's preclinical drug delivery programs. www.aurabiosciences.com

Dr. Fruehauf is VP, Research at Cequent Pharmaceuticals, Inc. and co-inventor of transkingdom RNAi (tkRNAi). At Cequent, Dr. Fruehauf directs the research and development of novel therapeutics based on Cequent's proprietary technology.

Managed a group of 3 postdoctoral fellows, 1 research assistant, 3 laboratory students Principal Investigator of a collaborative industry sponsored research grant, worth $1 MM. Managed in vivo preclinical drug discovery for 12 preclinical candidate cancer drugs from five different biological classes in this collaboration, responsible for entire project oversight, timelines, reports and communication Validated transkingdom RNAi in various disease models in vivo

Co-Inventor of transkingdom RNA interference (tkRNAi) (published in Nature Biotechnology 2006, US & International patents pending) Group leader for in vivo group Responsible for outside scientific collaborations, MTAs (in/out) Training and supervision of junior laboratory staff (graduate students, laboratory technicians)

Breast Cancer Clinical trials High Intensity Focused Ultrasound surgery Preeclampsia